novo nordisk cagrisema - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Hosted on MSN · 19h

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Benzinga.com · 1d

Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study.

Novo Nordisk Stock Rises

The New York Times · 14h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Investopedia on MSN · 23h

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

Reuters on MSN · 18h

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

14hon MSN

Novo doubles down on next-gen weight loss therapy despite early setback

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

22h

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

11h

Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

19h

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

6d

Novo Nordisk Shares Have a Long Road Back from 40% Slump

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

1d

Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - NVO

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results